Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.63 |
| ▸ | DRD4 | P21917 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618642 | 0.90 | CCR3 (0.64) | CCR3DRD4KCNH2CCR2KMT2A | |
| SCHEMBL5618852 | 0.89 | CCR3 (0.60) | CCR3DRD4KCNH2CCR2KMT2A | |
| SCHEMBL5771392 | 0.89 | CCR3 (0.60) | CCR3DRD4KCNH2CCR2KMT2A | |
| SCHEMBL5771404 | 0.87 | CCR3 (0.79) | CCR3DRD4KCNH2CCR2KMT2A | |
| SCHEMBL5778373 | 0.86 | CCR3 (0.57) | CCR3DRD4KCNH2CCR2KMT2A | |
| SCHEMBL5774092 | 0.86 | CCR3 (0.57) | CCR3DRD4KCNH2CCR2KMT2A | |
| SCHEMBL4496185 | 0.86 | CCR3 (0.68) | CCR3DRD4KCNH2KMT2ASIGMAR1 | |
| SCHEMBL3922376 | 0.86 | CCR3 (0.68) | CCR3DRD4KCNH2KMT2ASIGMAR1 | |
| SCHEMBL5777584 | 0.85 | CCR3 (0.68) | CCR3DRD4GAAKCNH2KMT2A | |
| SCHEMBL5776144 | 0.85 | CCR3 (0.56) | CCR3DRD4KCNH2CCR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240447-A2 | MORPHOLINE DERIVATES AS ANTIOBESITY AGENTS | AstraZeneca AB (Publ) (SE) | 2010-10-20 | — | — | EP | claimed |
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | claimed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| EP-2240447-A2 | MORPHOLINE DERIVATES AS ANTIOBESITY AGENTS | AstraZeneca AB (Publ) (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1586567-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203695-A1 | Compounds IV | GPR119, FABP4, LIPC | CCR3 2304/4885DRD4 2637/4885GAA 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.